Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Pyrotinib|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Docetaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide
Sponsor: The First Affiliated Hospital with Nanjing Medical University